Assessment cycle 2025 Q1
Documents ratified in the 2025 Q1 assessment cycle, which ran from 1 January 2025 to 31 March 2025 and was ratified on 18 March 2025.
Documents ratified
-
Record of documents ratified in the 2025 Q1 assessment cycle.
18 Mar 2025 -
Consultation on the third version of the semaglutide monograph. The revision incorporates the cardiovascular outcome evidence from SELECT, reported in the New England…
03 Apr 2025 -
Consultation on the terms governing the Institute's calculators. The draft states that a calculator implements a published formula, that it holds no user data, and that…
01 May 2025 -
Consultation on the print and archival format for Institute documents: what a printed copy must carry so that it remains checkable when detached from the site, and what…
02 May 2025 -
Consultation on the draft monograph for Dulaglutide, which the assessment committee released for public comment before ratification. The draft grades the compound's…
14 Mar 2025 -
Consultation on the draft monograph for GHK-Cu, which the assessment committee released for public comment before ratification. The draft grades the compound's principal…
27 Feb 2025 -
Consultation on the draft monograph for GHRP-2, which the assessment committee released for public comment before ratification. The draft grades the compound's principal…
30 Mar 2025 -
Consultation on the draft of CEI-MS-06, which specifies the performance a determination must achieve for microbiological quality and states what the resulting figure…
14 Apr 2025 -
Consultation on the draft of this intervention review, which registers the question: In adults at elevated cardiovascular risk, what is the effect of a glucagon-like…
20 Apr 2025 -
Consultation on the draft of this safety review, which registers the question: What is the incidence of gastrointestinal adverse events and of discontinuation for…
29 Mar 2025 -
Consultation on the draft of this scoping review, which registers the question: What randomised human evidence exists for BPC-157 in any indication?
22 Apr 2025 -
Consultation on the draft of this intervention review, which registers the question: In adults with type 2 diabetes, does tirzepatide achieve greater glycaemic and…
16 Apr 2025 -
What clinical evidence supports the uses under which growth-hormone secretagogues are supplied for research?
Very low26 May 2025 -
In adults with type 2 diabetes, does tirzepatide achieve greater glycaemic and weight effect than semaglutide?
High26 Apr 2025 -
In the population defined for obesity and overweight in adults, what is the effect of Retatrutide compared with the comparator used in its contributing trials on the…
Moderate17 May 2025 -
In the population defined for obesity and overweight in adults, what is the effect of Petrelintide compared with the comparator used in its contributing trials on the…
Low19 Jan 2026 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, what is the effect of Tirzepatide compared with the comparator…
Moderate13 Nov 2025 -
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with Semaglutide compared with its…
High08 May 2025 -
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with Orforglipron compared with its…
Moderate16 Jun 2025 -
In the population defined for type 2 diabetes mellitus, is the effect of Semaglutide maintained across the full duration of the contributing trials?
High18 Feb 2026 -
In the population defined for obesity and overweight in adults, is the effect of Retatrutide maintained across the full duration of the contributing trials?
Moderate16 Nov 2025 -
In the population defined for obesity and overweight in adults, is the effect of Liraglutide maintained across the full duration of the contributing trials?
High15 Nov 2025 -
In the population defined for type 2 diabetes mellitus, is the effect of Semaglutide, oral maintained across the full duration of the contributing trials?
High06 Aug 2025 -
Established atherosclerotic disease of the coronary, cerebral or peripheral arterial beds, or a risk profile sufficient for enrolment in a cardiovascular outcome trial.
23 Feb 2025 -
Steatotic liver disease with histological evidence of hepatocyte ballooning and lobular inflammation occurring in the context of at least one cardiometabolic risk…
18 Jan 2025 -
Symptomatic heart failure with a left ventricular ejection fraction of 50 % or above, occurring with obesity as a dominant phenotypic driver.
29 Jan 2025 -
Restoration of epithelial and dermal integrity following injury, assessed by closure rate, area reduction and scar quality.
08 Jan 2025 -
Domain-specific cognitive function or protection against cognitive decline, assessed by standardised neuropsychological batteries or clinical dementia rating.
15 Feb 2025 -
Dual glucagon and GLP-1 receptor agonist (oxyntomodulin analogue). Mazdutide reproduces the natural dual activity of oxyntomodulin with a pharmacokinetic profile suitable for weekly dosing. The glucagon arm…
Moderate22 Jun 2026 -
GLP-1 receptor agonist (cAMP-biased, acylated). Selective GLP-1 receptor agonism with a reported bias towards Gαs-coupled cyclic-AMP signalling. Whether signalling bias translates into a clinically…
Low27 Jun 2025 -
GIP receptor antagonist and GLP-1 receptor agonist conjugate (antibody–peptide). GLP-1 receptor agonism supplies appetite suppression; GIP receptor antagonism is proposed to act on adipose tissue and central pathways in…
Low19 May 2025 -
37-residue cationic antimicrobial host-defence peptide. LL-37 permeabilises bacterial membranes through an amphipathic helical mechanism and separately acts as a chemoattractant and immunomodulator through…
Low27 Apr 2026 -
Development and validation of a stability-indicating method for peptide preparations
High21 Aug 2025 -
Purity determination for peptides not retained by conventional reverse-phase chromatography
High20 Dec 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in peripheral arterial disease and type 2 diabetes randomising 792 participants over 52 weeks…
Moderate08 Dec 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in mash randomising 1,197 participants over 72 weeks for part 1. Primary result: Resolution in…
Moderate26 May 2025 -
Event-driven cardiovascular outcome trial, phase 3 study of Semaglutide, oral in cardiovascular and type 2 diabetes randomising 9,650 participants over median 47.5…
Moderate25 Aug 2025 -
Randomised, open-label, active-controlled, phase 3 study of Tirzepatide in obesity randomising 751 participants over 72 weeks. Primary result: Mean change −20.2 % with…
High28 May 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in knee osteoarthritis and obesity over 68 weeks. Primary result: Improvement relative to…
Low19 Dec 2025 -
Event-driven cardiovascular outcome trial, phase 3 study of Tirzepatide in cardiovascular and type 2 diabetes randomising 13,299 participants over median 4.5 years…
Moderate28 Nov 2025
page 1 of 3